Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,050.41 +39.81 (+0.79%) Dow
38,376.50 +136.52 (+0.36%) Nasdaq
15,622.67 +171.37 (+1.11%) Bitcoin USD
66,873.51 +571.62 (+0.86%) CMC Crypto 200
1,430.37 +15.61 (+1.10%)
Accuray Incorporated (ARAY)
| Previous close | 2.1700 |
| Open | 2.1800 |
| Bid | 2.1900 x 100 |
| Ask | 2.2200 x 100 |
| Day's range | 2.1700 - 2.2377 |
| 52-week range | 2.1000 - 4.3000 |
| Volume | |
| Avg. volume | 485,322 |
| Market cap | 218.667M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
- PR Newswire
Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.
- PR Newswire
New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to
